Tradestie Institutional Equity Comparison Engine

ZLAB vs APLS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

APLS Overall Edge

APLS Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Apellis Pharmaceuticals, Inc. Common Stock (APLS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ZLAB trades at N/M Forward P/E with -63.0% operating margin (-6.8% YoY revenue) versus APLS at 46.3x Forward P/E and 9.9% operating margin (+60.9% YoY). In options structure, ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro) against APLS sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner APLS
ZLAB N/M vs APLS 46.3x Fwd P/E
Growth & Margin Winner APLS
Op Margin -63.0% vs 9.9% ยท YoY -6.8% vs +60.9%
Momentum & Technical Winner APLS
1Y +9.7% vs +134.2% ยท 52W Pos 60% vs 100%
Options & Structure Winner APLS
UNCLASSIFIED (58th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap $3.0B
1M Return +2.76%
1Y Return +9.66%
Forward P/E N/M
Unified AI Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
APLS NASDAQ
Apellis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$41.03
-0.07% 1D
Market Cap $5.3B
1M Return +0.44%
1Y Return +134.19%
Forward P/E 46.3x
Unified AI Score
60.2 / 100 BUY
Tech 40.0 Fund 52.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZLAB +9.66% APLS +134.19% Spread: +112.92 pp (APLS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ZLAB TTM Op. Margin: -63.0% APLS TTM Op. Margin: 9.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs APLS. Trailing 12-month operating profitability (ZLAB -63.0% vs APLS 9.9%) and valuation multiples (ZLAB N/M vs APLS 46.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZLAB (0) vs APLS (10)
Institutional Metric ZLAB APLS Criterion Row Winner
Market Capitalization Scale $3.0B $5.3B Larger Scale APLS
Trailing P/E Ratio Valuation N/M 38.3x Lower Multiple APLS
Forward P/E Ratio Valuation N/M 46.3x Lower Multiple APLS
Revenue Growth (YoY) Growth -6.8% +60.9% Higher Growth APLS
Operating Margin (TTM) Profitability -63.0% 9.9% Higher Margin APLS
Net Profit Margin Profitability -44.9% 12.1% Higher Margin APLS
Return on Equity (ROE) Capital Efficiency -30.0% 46.0% Higher ROE APLS
52-Week Range Position Momentum 60% ($16โ€“$29) 100% ($16โ€“$41) Stronger Trend APLS
Beta / 30D Volatility Risk Regime 1.19ฮฒ ยท 78% Vol 4.54ฮฒ ยท 2% Vol Lower Realized Risk APLS
Unified Institutional Score Composite Signal 47.4 / 100 (HOLD) 60.2 / 100 (BUY) Higher Composite APLS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZLAB vs APLS Buy Guide
ZLAB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 58th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ZLAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
APLS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live APLS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZLAB nor APLS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.